Literature DB >> 6832934

Mechanism of the renal response to contrast medium in dogs. Decrease in renal function due to hypertonicity.

R W Katzberg, G Schulman, L G Meggs, W J Caldicott, M M Damiano, N K Hollenberg.   

Abstract

Radiographic contrast media (CM) (meglumine/sodium diatrizoate-76%; 1650 mOsm/kg) and other hypertonic solutions induce renal vasoconstriction by an unknown mechanism. In anesthetized dogs, renal blood flow (RBF) was measured with an electromagnetic flowmeter and filtration fraction (FF) and glomerular filtration rate (GFR) by the renal extraction of technetium-99m tin chelate. Ureteral pressure (UP) and wedged renal venous pressure (VP) were measured as indices of intrarenal pressure. Measurements of renal length (L), along with pressures, made it possible to examine the compliance of the system. A 4-cc intrarenal bolus of CM caused a 59% reduction in GFR (control: 0.63 +/- 0.04 to 0.26 +/- 0.04 ml/min X g, mean +/- SEM), in association with a 23% reduction in RBF (control: 3.10 +/- 0.11 to 2.39 +/- 0.26 ml/min X g) and a 44% decrease in FF (control: 0.32 +/- 0.01 to 0.18 +/- 0.03). These responses were compared with a 3-microgram intrarenal bolus of norepinephrine (NOREPI) which resulted in a 79.0 +/- 7.5% reduction in RBF, 68.3 +/- 7.3% reduction in GFR and 42.6 +/- 15.6% increase in FF. The NOREPI-induced vasoconstriction caused transient decreases in renal L, UP, and VP, whereas the CM-induced decrease in renal blood flow was associated with increases in these parameters. In studies employing ureteral occlusion to elevate intrarenal pressure, the magnitude (area, cm2) of the CM-induced decrease in renal perfusion was accentuated with increased UP (r = 0.79, n = 24, P less than 0.001). The CM-induced increase in renal L, UP, and VP must reflect osmotic forces and an increase in intrarenal pressure. The decreases in FF and GFR probably reflect Starling forces in the glomerular capillaries, with osmotic transients dominating. The results suggest a mechanical mechanism for the CM-induced decrease in RBF.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6832934     DOI: 10.1097/00004424-198301000-00015

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  7 in total

1.  Gadolinium contrast media are more nephrotoxic than iodine media. The importance of osmolality in direct renal artery injections.

Authors:  Barbara Elmståhl; Ulf Nyman; Peter Leander; Chun-Ming Chai; Klaes Golman; Jonas Björk; Torsten Almén
Journal:  Eur Radiol       Date:  2006-08-05       Impact factor: 5.315

2.  Intravenous urography with iopamidol in children with reflux and obstructive nephropathy: effects on glomerular and tubular functions and the renin-angiotensin-aldosterone system.

Authors:  M Bosio; F Bissoli; G Vignati; M G Fiori
Journal:  Pediatr Nephrol       Date:  1990-05       Impact factor: 3.714

Review 3.  Drug-induced nephrotoxicity. Aetiology, clinical features and management.

Authors:  A J Hoitsma; J F Wetzels; R A Koene
Journal:  Drug Saf       Date:  1991 Mar-Apr       Impact factor: 5.606

4.  Radiocontrast-induced renal failure.

Authors:  R T Misson; R E Cutler
Journal:  West J Med       Date:  1985-05

5.  Adenosine A1 receptors in contrast media-induced renal dysfunction in the normal rat.

Authors:  Per Liss; Per-Ola Carlsson; Fredrik Palm; Peter Hansell
Journal:  Eur Radiol       Date:  2004-01-09       Impact factor: 5.315

Review 6.  Hemodynamic and tubular changes induced by contrast media.

Authors:  Antonella Caiazza; Luigi Russo; Massimo Sabbatini; Domenico Russo
Journal:  Biomed Res Int       Date:  2014-02-11       Impact factor: 3.411

Review 7.  Is contrast medium osmolality a causal factor for contrast-induced nephropathy?

Authors:  Andreas M Bucher; Carlo N De Cecco; U Joseph Schoepf; Felix G Meinel; Aleksander W Krazinski; James V Spearman; Andrew D McQuiston; Rui Wang; Judith Bucher; Thomas J Vogl; Richard W Katzberg
Journal:  Biomed Res Int       Date:  2014-03-31       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.